LEHI, UT / ACCESSWIRE / October 31, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or "the Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today it has entered a Collaboration Agreement (the "Agreement") with True DNA Story LLC ("True DNA Story").
Under the terms of the Agreement, Frelii will incorporate True DNA Story's proprietary DNA alignment software and market their CLIA-validated health panels to the Company's medical network. True DNA Story will incorporate Frelii's patent-pending artificial intelligence program, NAVII, to improve the outputs of True DNA Story's CLIA-validated lab-developed tests.
"We are excited to partner with True DNA Story, signaling what we believe is a critical inflection point in the execution of our growth strategy." Stated Frelii CEO Ian Jenkins. "In addition to the positive impact on company revenues, we believe this agreement will help support our commitment to building long-term shareholder value." Jenkins added.
About Frelii Inc.
Frelii Inc. is a biotechnology company utilizing human DNA gene sequencing and artificial intelligence (AI) to assess more than 3.2 billion markers on the human genome. The resulting data provides valuable insight into an individual's DNA which are aligned and leveraged against its AI as a means of creating a robust data platform for use by a variety of sectors, including Health & Wellness, Healthcare, Medical Cannabis and Pharmaceutical.
About True DNA Story LLC
As a DNA alignment technology developer, True DNA Story delivers best-in-class speed and accuracy while analyzing the entire exome (where all human genes are located) with unmatched precision at a competitive cost.
For more information, please visit www.frelii.com or follow us online at:
Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii LinkedIn Page linkedin.com/company/frelii/
With questions or inquiries please contact: Seth Jones, sethjones@frelii.com
Safe Harbor Statement:
This release contains certain "forward-looking statements" relating to the business of the Company. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.
SOURCE: Frelii, Inc.
View source version on accesswire.com:
https://www.accesswire.com/564897/Frelii-Announces-Revenue-Sharing-Agreement-with-True-DNA-Story
